Alkem Laboratories ↗

Incorporated in 1973, Alkem has a track record of over five decades in the pharmaceutical industry. Alkem was founded by the late Samprada Singh, and his brother, Basudeo Singh, who is currently the company’s executive chairman with over four decades of industry experience. The company’s day-to-day operations are managed by a team of qualified and experienced management spearheaded by Sandeep Singh (grandson of Samprada Singh), who is currently the managing director of Alkem. Sandeep Singh

Alkem is the fifth-largest player in domestic formulation market with market share of 4.1% as on March 31, 2025 (PY: 4.02%) (Source: Company). Alkem has comprehensive product portfolio of over 800 brands with over 1,500 SKUs, spanning major therapy areas in acute and chronic segments, with four brands in top 50 and 18 brands among the top 300 domestic formulation brands (Source: Company). Alkem has been a leader in anti-infective therapy in the domestic market since last 15 years and ranks among

Alkem has developed large field force of over 12,500 medical representatives (MRs) and a nationwide supply chain and distribution network comprising over 8,800 stockists, over 75 depots and carrying and forwarding agents (CFA). The company has also expanded its international footprint organically and through few strategic acquisitions. Presently, Alkem operates in over 40 countries, including the US, Australia, the Philippines, Chile, Kazakhstan, Europe, the Middle East, and East Africa among ot

Alkem through its subsidiary, EBL, has ventured in development and distribution of biosimilar products. EBL focuses on development and production of biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. EBL is expanding in ~ biosimilar space supported by its existing Pune facility and the new US plant, built with a significant capital outlay of ₹700 crore, which began operations in Q1FY26. It offers a range of biologics CDMO and contact manufacturing operation [CMO] services

In FY25, Alkem’s revenue remained largely stable at ₹13,003 crore (FY24: ₹12,668 crore), aided by domestic and RoW revenue growth, which was partially offset by ~10% decline in the US market. PBILDT margin expanded by 197 bps to 19.72% (FY24: 17.75%) due to the focus on higher-margin products, decline in raw material prices and cost control measures undertaken by the company. In H1FY26, Alkem reported TOI of ₹7,372 crore marking a y -o-y growth of 15%, driven by strong volume expansion in the

Alkem’s capital structure continued to remain comfortable marked by overall gearing and total outside liabilities to tangible net worth (TOL/TNW) of 0.13x and of 0.44x, respectively, as on March 31, 2025. The company operates at strong net worth base of ₹11,992 crore as on March 31, 2025. Going forward, CareEdge Ratings expects the company’s overall gearing to remain comfortable below 0.20x over FY26-FY28, despite availing debt of US$ 50 million for establishment of a biosimilar facility in the

Alkem earned ~80 -85% revenue from the acute therapeutic segment, which is a relatively slow -growing and less margin -accretive segment. Around 30% products fall under the DPCO, which restricts the pricing power and restricts profitability. In recent ye ars, Alkem is consciously increasing its focus on the chronic and sub -chronic segment products, including neuro and CNS, cardiac, 3 CARE Ratings Ltd. Press Release anti-diabetic, and dermatology. Alkem also entered ophthalmic therapeutic segmen

Alkem has its presence in multiple countries across the world. It has 18 manufacturing units including one in the US. Considering the product usage and application, and consequent impacts, Alkem is required to comply with laws, rules and regulations and operate under strict regulatory environment. Thus, infringement in of the law, and significant adverse change in the i mport/export policy or environmental/regulatory policies in the company’s operations, can have an impact. The company is contin